Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)

Hiu Yan Jennifer Lee, Mingjing Meng, Yulong Liu, Tao Su, Hiu Yee Kwan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer is the leading cause of cancer‑related mortality worldwide. Non‑small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Patients harboring epidermal growth factor receptor (EGFR) mutations usually develop resistance to treatment with frontline EGFR‑tyrosine kinase inhibitors (EGFR‑TKIs). The present review summarizes the current findings and delineates the molecular mechanism of action for the therapeutic effects of herbal extracts and phytochemicals in overcoming EGFR‑TKI resistance in NSCLC. Novel molecular targets underlying EGFR‑TKI resistance in NSCLC are also discussed. This review provides valuable information for the development of herbal bioactive compounds as alternative treatments for EGFR‑TKI‑resistant NSCLC.
Original languageEnglish
Article number646
Number of pages10
JournalOncology Letters
Volume22
Issue number3
Early online date8 Jul 2021
DOIs
Publication statusPublished - Sep 2021

User-Defined Keywords

  • non‑small cell lung cancer
  • epidermal growth factor receptor
  • herbal medicine
  • Chinese medicine
  • drug resistance

Fingerprint

Dive into the research topics of 'Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)'. Together they form a unique fingerprint.

Cite this